Upcoming event

Development and validation of a nomogram predicting intraoperative adverse events during robot-assisted partial nephrectomy

European Urology Focus, September 2022

A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: Proposal from the European Association of Urology guidelines panel

European Urology, October 2022

Stereotactic ablative radiation for systemic therapy–naïve oligometastatic kidney cancer

European Urology Oncology, August 2022

Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

September 2022

Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

September 2022

IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

September 2022

Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

September 2022

Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

September 2022

Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003

, September 2022

Phase 2 KEYNOTE-B61 Study of Pembrolizumab (Pembro) + Lenvatinib (Lenva) as First-Line Treatment for Non-Clear Cell Renal Cell Carcinoma (nccRCC)

Protective effect of LCZ696 on kidney function after partial nephrectomy

Adjuvant therapy after surgical resection of nonmetastatic renal-cell carcinoma: One size does not fit all